Table of contents
June 2016 - Volume 75 - Suppl 2
- Abstracts Accepted for Publication
- Rheumatoid arthritis - anti-TNF therapy
- SLE, Sjögren's and APS - etiology, pathogenesis and animal models
- Adaptive immunity (T cells and B cells) in rheumatic diseases
- Innate immunity in rheumatic diseases
- Cytokines and inflammatory mediators
- Rheumatoid arthritis - prognosis, predictors and outcome
- Rheumatoid arthritis - comorbidity and clinical aspects
- Cartilage, synovium and osteoimmunology
- Rheumatoid arthritis - etiology, pathogenesis and animal models
- Rheumatoid arthritis - other biologic treatment
- Rheumatoid arthritis - non-biologic treatment and small molecules
- SLE, Sjögren's and APS - clinical aspects (other than treatment)
- Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models
- Basic science in paediatric rheumatology
- SLE, Sjögren's and APS - treatment
- Scleroderma, myositis and related syndromes
- Spondyloarthritis - treatment
- Spondyloarthritis - clinical aspects (other than treatment)
- Osteoarthritis
- Osteoporosis
- Psoriatic arthritis
- Crystal diseases, metabolic bone diseases and bone diseases other than osteoporosis
- Infection-related rheumatic diseases
- Fibromyalgia
- Back pain, mechanical musculoskeletal problems, local soft tissue disorders
- Paediatric rheumatology
- Other orphan diseases
- Diagnostics and imaging procedures
- Epidemiology, health services and outcome research
- Epidemiology, health services and outcome research
- Rehabilitation
- Education
- Nursing
- Psychology / Social sciences
- Physiotherapy
- Occupational therapy
- Miscellaneous forms of clinical care
- Poster Presentations
- Cytokines and inflammatory mediators
- Rheumatoid arthritis - etiology, pathogenesis and animal models
- Rheumatoid arthritis - prognosis, predictors and outcome
- Rheumatoid arthritis - comorbidity and clinical aspects
- Rheumatoid arthritis - anti-TNF therapy
- Rheumatoid arthritis - other biologic treatment
- Scleroderma, myositis and related syndromes
- Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models
- SLE, Sjögren's and APS - clinical aspects (other than treatment)
- Vasculitis
- Vasculitis
- Spondyloarthritis - clinical aspects (other than treatment)
- Psoriatic arthritis
- Other orphan diseases
- Diagnostics and imaging procedures
- Education
- Physiotherapy & miscellaneous forms of clinical care
- Epidemiology, health services and outcome research
- Rheumatoid arthritis - etiology, pathogenesis and animal models
- Rheumatoid arthritis - prognosis, predictors and outcome
- Rheumatoid arthritis - comorbidity and clinical aspects
- Rheumatoid arthritis - other biologic treatment
- Genomics, genetic basis of disease and HLA/T cell recognition
- Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models
- Scleroderma, myositis and related syndromes
- Paediatric rheumatology
- SLE, Sjögren's and APS - clinical aspects (other than treatment)
- Vasculitis
- Nursing
- Psychology/Social sciences
- Miscellaneous forms of clinical care
- Occupational therapy
- Adaptive immunity (T cells and B cells) in rheumatic diseases
- Cartilage, synovium and osteoimmunology
- Rheumatoid arthritis - prognosis, predictors and outcome
- Rheumatoid arthritis - non-biologic treatment and small molecules
- SLE, Sjögren's and APS - clinical aspects (other than treatment)
- Osteoporosis
- SLE, Sjögren's and APS - etiology, pathogenesis and animal models
- ER stress & rheumatic disease
- Joint EULAR - EFIS session: Do stromal cells house and cure immune cells?
- Role of imaging in childhood-onset rheumatic diseases
- Oral Presentations
- Global year against joint pain
- Diagnosis and management of SSc
- Developing evidence-based non-pharmacological care
- Cartilage, bone, synovium
- SpA and PsA basic and translational research
- SpA and PsA clinical
- Clinical osteoporosis: new insights
- Expanding therapeutic options in spondyloarthritis
- Designing solutions to support young people to address the challenges of living with a rheumatic or musculoskeletal disease
- New insights into imaging
- Advancements in the imaging of PsA
- When and how to treat Raynaud's phenomenon and related complications
- Role of new imaging techniques as RMD outcomes
- “Fewer words - more action” - tailored care for men with rheumatic diseases?
- Recent advances in our understanding of macrophage biology
- Lubricants: potential as osteoarthritis treatment?
- Extraarticular complications of JIA
- The elephant in the room: how to avoid biases in research?
- Digital applications for the benefit of the patient
- Optimization of MTX in RA treatment
- Joint replacement in OA: friend or foe?
- How to identify and follow patients with inflammatory back pain?
- Physical activity assessment - what do we know, what do we do, how does it work?
- How cell death shapes immunity and tolerance
- “Smoke a joint to protect the joint”
- Clinical relevance of immunogenicity and therapeutic drug monitoring
- Outcome measures in clinical practice in gout and CPPD
- Cormobidities
- Biomarkers: powerful or powderpuff?
- The role of nuclear medicine in rheumatology
- PROMs/PROs in rheumatological research - time for a critical appraisal?
- Collaboration for success
- Hand osteoarthritis: state of the art and future perspectives
- News from kinase inhibitors
- Crystal arthritis
- New pathways to treatment
- Epidemiology of RMDs
- Prognosis and outcome in RA
- SLE, Sjögren's and APS: clinical aspects (other than treatment)
- Shared decision making
- Novel insights into B and T cell immunity in rheumatic disease
- An inflammatory update!
- Advances in paediatric rheumatology
- New horizons in osteoarthiritis
- Teaching clinical skills
- What is done for people with rare diseases? Can we do more?
- The Health Professionals' approach to pain management in inflammatory arthritis and osteoarthritis
- Developments in the treatment of RA
- Speaker Presentations
- Recent advances in our understanding of macrophage biology
- Outcome measures in clinical practice in gout and CPPD
- Lubricants: potential as osteoarthritis treatment?
- Extraarticular complications of JIA
- The elephant in the room: how to avoid biases in research?
- Digital applications for the benefit of the patient
- EULAR projects in Clinical Affairs
- Optimization of MTX in RA treatment
- Joint replacement in OA: friend or foe?
- Physical activity assessment - what do we know, what do we do, how does it work?
- How cell death shapes immunity and tolerance
- “Smoke a joint to protect the joint”
- EULAR - EMA session
- Teaching clinical skills
- Local procedures including aspirations, injections and biopsies I
- MRI I
- The Health Professionals' approach to pain management in inflammatory arthritis and osteoarthritis
- News from kinase inhibitors
- Crystal arthritis
- HOT session 7
- WIN session 1
- Catastrophizing pain in RA
- Axial spondyloarthritis and psoriatic arthritis: emerging pathways
- HOT session 1
- Balancing benefits and risk of glucocorticoids; a challenge for implementation
- What CVD outcomes to use in clinical rheumatological practice?
- Different perspectives on pain in osteoarthritis
- Epigenetics solving the OA puzzle
- Muscle biology & inflammation
- Lessons from the children (monogenic causes of autoimmunity)
- ABC of statistics
- WIN session 8
- The elderly patient with osteoarthritis
- SLE: what will it be and how will it be treated 5 years from now
- HOT session 10
- “Time is joint”: early recognition and treatment of arthritis
- Clinical outcomes for PMR/GCA
- Getting active against rheumatoid arthritis fatigue
- Endothelial to mesenchymal transition and angiogenesis as driving mechanisms in systemic sclerosis
- Cell-cell interaction in joint inflammation
- Transition of care
- New approaches to understanding and managing chronic musculoskeletal pain
- Seronegative inflammatory arthritis: diagnostic and management challenges
- HOT session 11
- Paget's and other rare bone diseases
- Analytical issues of complex databases
- Intimate life and sexual relations in RA
- Data visualisation: tables and graphs for publication and presentation I
- Ultrasound basic I
- Patient organisations in action
- Hot topics in paediatric rheumatology
- Plasma cells as key players and therapeutic target in rheumatic diseases
- Global year against joint pain
- HOT session 4
- Designing solutions to support young people to address the challenges of living with a rheumatic or musculoskeletal disease
- WIN session 3
- Advancements in the imaging of PsA
- When and how to treat Raynaud's phenomenon and related complications
- Role of new imaging techniques as RMD outcomes
- “Fewer words - more action” - tailored care for men with rheumatic diseases?
- WIN session 6
- Difficult to treat rheumatoid arthritis
- Biomarkers: powerful or powderpuff?
- HOT session 8
- The role of nuclear medicine in rheumatology
- PROMs/PROs in rheumatological research - time for a critical appraisal?
- Collaboration for success
- ER stress & rheumatic disease
- Role of imaging in childhood-onset rheumatic diseases
- Physician-patient relationship in the era of interactive media
- Capillaroscopy II
- Ultrasound advanced I
- It's in your hands
- The EULAR School of Rheumatology - a new era of education
- Vaccination in rheumatic patients: a two-edged sword
- Advances in large vessel vasculitis
- HOT session 9
- When and how to diagnose and treat vitamin D deficiency?
- Data harmonization across (rheumatoid arthritis) clinical cohorts and registers
- Telemedicine and e-health in community care
- Inflammasome as therapeutic target in inflammatory diseases
- What's new: latest advances in treatment and management of systemic sclerosis and fibromyalgia
- EULAR projects in Investigative Rheumatology
- Bone and heart: common molecular mechanisms in osteoporosis and atherosclerosis
- Adiposity as a driver of arthritis through inflammatory mechanisms
- EULAR educational offer
- There is more than drugs